BIOTECH ASSISTANT / FIELD NOTES

Wave outlines WVE-006 development plans and WVE-007 Phase 2a studies

Company / institutional announcement · Wave Life Sciences

Source published: 2026-10-27 · Event / reporting date: 2026-10-27

Site published: 2026-11-04 · Updated: 2026-11-04

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What changed

Wave's quarterly update describes planning for a registrational WVE-006 RNA-editing study in AATD and ongoing WVE-007 siRNA Phase 2a work. The company also reports FDA support for its LC-MS assay in the planned WVE-006 program. Regulatory feedback and trial plans do not constitute marketing approval or comparative efficacy evidence.

Why it may matter

Potential business relevance: track disclosed capabilities or development plans; independent validation and project-specific applicability still require review.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Oligonucleotide Therapeutics & Delivery Bioanalysis & Biomarkers

Follow the evidence

No explicit catalog company name was matched. These are companies in the same field, not attributed participants.

WuXi AppTec / WuXi TIDES Pharmaron Medicilon Charles River Laboratories Nuvisan

Explore field companies →Explore literature →

Related updates

2026-11-06Phio Pharmaceuticals

Phio schedules final PH-762 Phase 1b findings and plans Phase 2b in 2027

Phio announced a November 7 SITC oral presentation of final Phase 1b findings for intratumoral PH-762, its PD-1-silencing siRNA candidate, in cutaneous carcinomas. The company described tolerability and potential tissue-sparing neoadjuvant use, while stating that additional safety and efficacy studies are needed. A Phase 2b study is planned for the first half of 2027.

Oligonucleotide Therapeutics & Delivery Ask AI ↗

2026-11-06Vir Biotechnology / Business Wire

Vir schedules Phase 3 elebsiran–tobevibart results for The Liver Meeting

Vir Biotechnology announced that Phase 3 ECLIPSE 1 results for elebsiran plus tobevibart in chronic hepatitis delta will be presented on November 8, with an investor discussion on November 9. Elebsiran is an HBV-targeting siRNA; tobevibart is an antibody. The release announces the forthcoming readout and expanded Phase 2 presentations but does not disclose the Phase 3 numerical results.

Oligonucleotide Therapeutics & Delivery Ask AI ↗

2026-11-05Nature Communications

Peptide–oligonucleotide nanohybrids deliver miRNA to injured bone in rats

A Nature Communications study reports a peptide–oligonucleotide nanohybrid for bone-targeted miR-26a-5p delivery. The original abstract describes reduced GSK-3β expression and stabilization of HIF-1α, supporting coupled bone formation and angiogenesis. Systemic administration limited skeletal and vascular injury in a rat glucocorticoid-induced bone-loss model. This is preclinical miRNA delivery, not oral cyclic peptide therapy or human efficacy evidence.

Oligonucleotide Therapeutics & Delivery Formulation Development & Manufacturing Ask AI ↗

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗